Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cambrex Corp (CBM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,918,373
  • Shares Outstanding, K 32,570
  • Annual Sales, $ 490,640 K
  • Annual Income, $ 81,680 K
  • 36-Month Beta 2.28
  • Price/Sales 3.91
  • Price/Cash Flow 16.57
  • Price/Book 4.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.05 +5.08%
on 07/06/17
61.70 -4.54%
on 06/23/17
-0.35 (-0.59%)
since 06/21/17
3-Month
51.35 +14.70%
on 05/15/17
62.95 -6.43%
on 05/04/17
+3.00 (+5.37%)
since 04/21/17
52-Week
38.30 +53.79%
on 11/03/16
62.95 -6.43%
on 05/04/17
+0.05 (+0.08%)
since 07/21/16

Most Recent Stories

More News
Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer

Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced today that Andrew G. Long has joined the company as Chief Financial Officer, effective August 7, 2017.

INSY : 11.98 (-2.68%)
CBM : 58.90 (+0.08%)
Zacks.com featured highlights: Hitachi, Koninklijke DSM, Embotelladora Andina, Cambrex and Ituran Location and Control

Zacks.com featured highlights: Hitachi, Koninklijke DSM, Embotelladora Andina, Cambrex and Ituran Location and Control

HTHIY : 66.1000 (+0.29%)
ITRN : 30.85 (-0.48%)
RDSMY : 18.5200 (unch)
AKO.B : 25.72 (-0.19%)
CBM : 58.90 (+0.08%)
5 Top Stocks with Solid Net Profit Margin

Net profit margin is the most effective way to measure a company's profitability.

HTHIY : 66.1000 (+0.29%)
ITRN : 30.85 (-0.48%)
AKO.B : 25.72 (-0.19%)
RDSMY : 18.5200 (unch)
CBM : 58.90 (+0.08%)
The Zacks Analyst Blog Highlights: Lantheus Holdings, Cambrex, Health Insurance Innovations, Anthem and American Equity Investment Life Holding

The Zacks Analyst Blog Highlights: Lantheus Holdings, Cambrex, Health Insurance Innovations, Anthem and American Equity Investment Life Holding

LNTH : 18.55 (unch)
HIIQ : 28.05 (+0.90%)
ANTM : 190.65 (-0.02%)
AEL : 28.00 (+0.72%)
CBM : 58.90 (+0.08%)
Republicans Present Healthcare Bill: Top 5 Gainers

Healthcare stocks posted record highs, with hospitals and insurers climbing after Senate Republicans released a draft bill to replace Obamacare.

XPH : 44.32 (+0.18%)
LNTH : 18.55 (unch)
MOH : 71.15 (-1.25%)
HCA : 85.73 (-0.03%)
AEL : 28.00 (+0.72%)
HIIQ : 28.05 (+0.90%)
ANTM : 190.65 (-0.02%)
CNC : 84.73 (-0.78%)
XBI : 80.77 (+0.79%)
THC : 20.65 (-0.10%)
CBM : 58.90 (+0.08%)
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics

The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics

AVXL : 4.21 (-13.55%)
GERN : 2.80 (-0.36%)
HSGX : 1.95 (-1.02%)
CBM : 58.90 (+0.08%)
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys

IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.

ESPR : 47.71 (-2.23%)
PBYI : 94.30 (-0.47%)
AVXL : 4.21 (-13.55%)
IBB : 324.88 (+0.61%)
VRTX : 163.17 (+2.41%)
GERN : 2.80 (-0.36%)
REGN : 515.92 (-1.00%)
KITE : 109.15 (-0.67%)
CALA : 15.55 (-1.89%)
HSGX : 1.95 (-1.02%)
CBM : 58.90 (+0.08%)
Cambrex Reports First Quarter 2017 Financial Results

- Net Revenue increased 11% and EBITDA increased 26% vs. prior year quarter -

CBM : 58.90 (+0.08%)
Cambrex to Announce First Quarter 2017 Financial Results on May 4, 2017

Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2017 financial results will be...

CBM : 58.90 (+0.08%)
SmarTrend Watching for Potential Pullback in Shares of Cambrex After 4.38% Gain

Cambrex (NYSE:CBM) traded in a range yesterday that spanned from a low of $53.00 to a high of $55.60. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $53.35 on...

CBM : 58.90 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance...

See More

Support & Resistance

2nd Resistance Point 60.03
1st Resistance Point 59.47
Last Price 58.90
1st Support Level 58.57
2nd Support Level 58.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.